Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

40 results
Display

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations

Duggirala KB, Lee Y, Lee K

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase widely expressed in many cancers such as non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad

Kang JH, Jang YS, Lee HJ, Lee CY, Shin DY, Oh SH

Signal transducer and activator of transcription 3 (STAT3) modulates a variety of genes involved in the regulation of critical functions, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, and immunity. For...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer

Lee JM, Kim T, Kim EY, Kim A, Lee DK, Kwon NH, Kim S, Chang YS

PURPOSE: Identification of lymph node (LN) metastasis in non-small cell lung cancer (NSCLC) is critical for disease staging and selection of therapeutic modalities. Sometimes it is not possible to obtain...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

Cho JH

Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Moderate hypofractionated image-guided thoracic radiotherapy for locally advanced node-positive non-small cell lung cancer patients with very limited lung function: a case report

Manapov F, Roengvoraphoj O, Li M, Eze C

Patients with locally advanced lung cancer and very limited pulmonary function (forced expiratory volume in 1 second [FEV1] ≤ 1 L) have dismal prognosis and undergo palliative treatment or best...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists

O'Neill AC, Jagannathan JP, Ramaiya NH

Traditionally tumors were classified based on anatomic location but now specific genetic mutations in cancers are leading to treatment of tumors with molecular targeted therapies. This has led to a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correlation Analysis and Prognostic Impact of 18F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer

Jeong YH, Lee CK, Jo K, Hwang SH, Cha J, Lee JW, Yun M, Cho A

PURPOSE: The aim of this study was to determine the relationship between [18]-2-fluoro-2-deoxy-D-glucose (FDG) uptake and excision repair cross-complementation group 1 (ERCC-1) expression and to evaluate the prognostic effect of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer

Jung IH, Song SY, Jung J, Cho B, Kwak J, Je HU, Choi W, Jung NH, Kim SS, Choi EK

PURPOSE: To evaluate the treatment results in early stage non-small cell lung cancer patients who have undergone fiducial-less CyberKnife radiosurgery (CKRS). MATERIALS AND METHODS: From June 2011 to November 2013, 58...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Role of Loss of O(6)-Methylguanine DNA Methyltransferase (MGMT) Expression in Non-Small Cell Lung Carcinomas (NSCLCs): with Reference to the Relationship with p53 Overexpression

Myong NH

  • KMID: 2165964
  • Cancer Res Treat.
  • 2010 Jun;42(2):95-100.
PURPOSE: Functional inactivation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene has been demonstrated as loss of MGMT protein and suggested that it plays an important role in primary human neoplasia, including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis

Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, Chang YS

BACKGROUND/AIMS: The insulin-like growth factor (IGF) system has been implicated in tumor growth, invasion, and metastasis. However, reports on the IGF-1 receptor (IGF-1R) based on radioimmunoassays are conflicting, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Targeted Therapy of Lung Cancer

Lee KY

Atherapeutic plateau has been reached with classical cytotoxic agents in the management of advanced non-small cell lung cancer (NSCLC) patients, even though there has been some modest improvement in overall...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunohistochemical Analysis for the Expression of DR5 TRAIL Receptor and p53 in Non-small Cell Lung Cancer

Lee KY, Lee JH, Kim SJ, Yoo KH

BACKGROUND: TRAIL is a promising anticancer agent which induces selective tumor cell death due to a unique receptor system that includes death receptors and decoy receptors. DR5 TRAIL receptor is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and Prognostic Factors of Radiation Pneumonitisin NSCLC Treated with Intensity Modulated Radiation Therapy (IMRT)

Kim MS

PURPOSE: To evaluate the incidence and prognostic factors of treatment-related pneumonitis in non-small-cell lung cancer (NSCLC) patients treated with intensity modulated radiation therapy (IMRT). MATERIALS AND METHODS: One-hundred-five patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
High Frequency of Genetic Alterations in Non-small Cell Lung Cancer Detected by Multi-target Fluorescence In Situ Hybridization

Kang JU, Koo SH, Kwon KC, Park JW, Shin SY, Kim JM, Jung SS

Detection of genetic alterations could provide a tool as an adjuvant for the diagnosis of non-small cell lung cancer (NSCLC) and to define patients at risk for early relapse. In...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Paclitaxel and Cisplatin with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Stage IIIB Non-small Cell Lung Cancer

Kang KM, Lee GW, Kim HG, Kang JH, Lee WS, Chai GY

  • KMID: 2003454
  • J Korean Soc Ther Radiol Oncol.
  • 2006 Dec;24(4):223-229.
PURPOSE: Combined modality therapy including chemotherapy, surgery and radiotherapy is considered the standard of care for the treatment of stage III non-small cell lung cancer (NSCLC). This study was conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Promoter -202 A/C Polymorphism of Insulin-like Growth Factor Binding Protein-3 Gene and Non-small Cell Lung Cancer Risk

Moon JW, Chang YS, Han CH, Kang SM, Park MS, Byun MK, Chung WY, Park JJ, Yoo KN, Shin JH, Kim YS, Chang J, Kim SK, Kim HJ, Kim SK

  • KMID: 2318548
  • Tuberc Respir Dis.
  • 2005 Apr;58(4):359-366.
BACKGROUND: IGFBP-3 inhibits the mitogenic and anti-apoptotic activity of IGF by blocking the binding of IGF to its receptor. However, under certain circumstances, IGFBP- 3 can enhance the activity of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multimodality Treatement in Patients with Clinical Stage IIIA NSCLC

Lee YS, Jang PS, kang HM, Lee JE, Kwon SJ, An JY, Jung SS, Kim JO, Kim SY

BACKGROUND: To find out effectiveness of multimodality treatments based on induction chemotherapy(CTx) in patients with clinical stage IIIA NSCLC METHODS: From 1997 to 2002, 74 patients with clinical stage IIIA NSCLC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of PET in Staging Non-Small Cell Lung Cancer

Hyun IY

  • KMID: 1990845
  • Korean J Nucl Med.
  • 2004 Dec;38(6):481-485.
Lung cancer has become a leading cause of cancer death in Korea. Accurate staging of non-small cell lung cancer (NSCLC) is essential to the ability to offer a patient the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concurrent Chemoradiation with Weekly Paclitaxel in Locally Advanced Non-small Cell Lung Cancer

Bae KW, Song TH, Yang JY, Kim YS, Park JS, Jee YK, Lee KY

  • KMID: 2318500
  • Tuberc Respir Dis.
  • 2004 Oct;57(4):351-357.
BACKGROUND: Paclitaxel is highly beneficial anticancer drug for the treatment of non-small cell lung cancer and has shown remarkable radiosensitizing effect in vitro. We evaluated whether concurrent chemoradiation therapy with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
3-week-scheduled combination chemotherapy of gemcitabine and cisplatin in patients with advanced NSCLC

Kim SH, Lee GW, Yoon JH, Shim KS, Lee YM, Kang DY, Park JR, Jung JH, Shin MK, Jeong YY, Kim HC, Lee WS, Lee JD, Hwang YS, Lee JS, Jang JS

  • KMID: 2252685
  • Korean J Med.
  • 2004 Jan;66(1):58-66.
BACKGROUND: The combination chemotherapy of gemcitabine and cisplatin has been proven effective in the treatment of advanced non-small cell lung cancer (NSCLC). However, the optimal schedule for administration of the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr